Asia-Pacific IBD market is estimated to grow significantly at a CAGR of around 5.5% during the forecast period. The major economies which are contributing to the market are China, India, and Japan. The market growth in China and India is attributed to the growing healthcare infrastructure due to substantial government spending in the healthcare sector. Rapid urbanization and changing eating habits are also supposed to grow the market substantially in the region. Japan contributes considerably in the IBD market due to growing awareness regarding IBD and the established healthcare industry. Along with these economies, Australia, Indonesia, and Thailand are other major countries with advanced healthcare facilities and projected to show a significant growth rate during the forecasted period.  

Asia-Pacific IBD market is segmented on the basis of disease type, diagnostics, and therapeutics. Asia-Pacific IBD market is segmented on the basis of disease type into ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. On the basis of diagnostics, the market segmented into blood and stool, endoscopies, ultrasound, and X-rays. Endoscopy is a conventional diagnostic method that is widely being used for the diagnosis of IBD and having a considerable share in the market. The therapeutics segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD. 

The companies which are contributing to the growth of the Asia-Pacific IBD market include AbbVie Inc., Allergan, PLC, Boehringer Ingelheim International GmbH, Eli Lilly and Co., Daiichi Sankyo Co. Ltd., Mercator Pharmaceutical Solutions  Johnson & Johnson Services Inc., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Co., Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market. 

Research Methodology

The market study of Asia-Pacific IBD market is incorporated by extensive primary and secondary research conducted by the research team.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

Market Segmentation

1. Asia-Pacific IBD Market Research and Analysis by Disease Type
2. Asia-Pacific IBD Market Research and Analysis by Diagnostics
3. Asia-Pacific IBD Market Research and Analysis by Therapeutics

The Report Covers

• Comprehensive research methodology of the Asia-Pacific IBD market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Asia-Pacific IBD market.
• Insights about market determinants which are stimulating the Asia-Pacific IBD market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.